Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 5

1.

Phosphatidylinositol-3-kinase pathway mutations are common in breast columnar cell lesions.

Troxell ML, Brunner AL, Neff T, Warrick A, Beadling C, Montgomery K, Zhu S, Corless CL, West RB.

Mod Pathol. 2012 Jul;25(7):930-7. doi: 10.1038/modpathol.2012.55. Epub 2012 Mar 30.

2.

The favorable impact of PIK3CA mutations on survival: an analysis of 2587 patients with breast cancer.

Dumont AG, Dumont SN, Trent JC.

Chin J Cancer. 2012 Jul;31(7):327-34. doi: 10.5732/cjc.012.10032. Epub 2012 May 24. Review.

3.
4.

PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical data.

Zardavas D, Phillips WA, Loi S.

Breast Cancer Res. 2014 Jan 23;16(1):201. doi: 10.1186/bcr3605. Review.

5.

Investigating the Inhibitory Effect of Wortmannin in the Hotspot Mutation at Codon 1047 of PIK3CA Kinase Domain: A Molecular Docking and Molecular Dynamics Approach.

Kumar DT, Doss CG.

Adv Protein Chem Struct Biol. 2016;102:267-97. doi: 10.1016/bs.apcsb.2015.09.008. Epub 2015 Oct 29. Review.

PMID:
26827608

Supplemental Content

Write to the Help Desk